Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non–muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis

Fukuokaya, Wataru; Kimura, Takahiro; Miki, Jun; Kimura, Shoji; Watanabe, H; Fan, Bo; Okada, Daigo; Aikawa, Koichi; Ochi, Atsuhiko; Suzuki, Koichiro; Shiga, Naoki; Abe, Hirokazu; Egawa, Shin

doi:10.1016/j.clgc.2019.09.005

Cited by 9 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doxorubicin is the most widely used anthracycline, used in the treatment of malignancies such as breast cancer, bladder cancer, or lymphoma (EBCTCG, 2005;Gianni et al, 2009;Lori et al, 2010;Fukuokaya et al, 2020). The cancer treatment effectiveness of Doxorubicin is, however, accompanied by severe cardiotoxicity, and as a result it has been increasingly replaced by epirubicin, an epimer associated with milder adverse effects (Khasraw et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Circulating Levels of Epirubicin Cause Endothelial Senescence While Compromising Metabolic Activity and Vascular Function

Eakin

Erlain

Burke

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Anthracycline-based chemotherapy is a common treatment for cancer patients. Because it is delivered intravenously, endothelial cells are exposed first and to the highest concentrations, prior to diffusion to target cells. Not surprisingly, vascular dysfunction is a consequence of anthracycline therapy. While chemotherapy-induced endothelial damage at administration sites has been investigated, the effects of lower doses encountered by distant microvascular networks has not. The aim of this study was to investigate the impact of epirubicin, a widely used anthracycline, on healthy endothelial cells to elucidate its effects on microvascular physiology. Here, endothelial cells were briefly exposed to low doses of epirubicin to recapitulate levels in circulation following dilution in the blood and compound half-life in circulation. Both immediate and prolonged responses to treatment were assessed to determine changes in endothelial function. Epirubicin caused a decrease in proliferation and viability in hUVEC, with lower doses resulting in a senescent phenotype in a large proportion of cells, accompanied by a significant increase in pro-inflammatory cytokines and a significant decrease in metabolic activity. Epirubicin exposure also impaired endothelial function with delayed wound closure, reduced angiogenic potential and increased monolayer permeability downstream of VE-cadherin internalization. Primary lung endothelial cells obtained from epirubicin-treated mice similarly demonstrated reduced viability and functional impairment. In vivo, epirubicin treatment resulted in persistent reduction in lung vascular density and significantly increased infiltration of myeloid cells. Modulation of endothelial status and inflammatory tissue microenvironment observed in response to low doses of epirubicin may predict risk for long-term secondary pathologies associated with chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Circulating Levels of Epirubicin Cause Endothelial Senescence While Compromising Metabolic Activity and Vascular Function

Eakin

Erlain

Burke

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…[1][2][3] It is reported that the incidence of bladder cancer is still increasing. 4,5 Furthermore, bladder cancer presents a high recurrence rate and mortality rate because of the absence of typical symptoms at the early stage. 6,7 No reliable biomarkers are helpful for clinical therapy and survival estimation.…”

Section: Introductionmentioning

confidence: 99%

<p>Ribosome Binding Protein 1 Correlates with Prognosis and Cell Proliferation in Bladder Cancer</p>

Shi

Wang

et al. 2020

OTT

View full text Add to dashboard Cite

Introduction Ribosome binding protein 1 (RRBP1) is reported to be correlated with tumor formation and progression. However, the role of RRBP1 in bladder cancer is unclear. In this study, we aimed to investigate the expression of RRBP1 and its influence on cell proliferation in bladder cancer. Methods Quantification real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) were used to detect the expression levels of RRBP1 in 138 bladder cancer and matched adjacent normal bladder tissues. Then, the clinical significance of RRBP1 in bladder cancer was evaluated. The effect of RRBP1 on cell proliferation and its potential mechanism were further explored. Results Results show that the mRNA levels of RRBP1 in bladder cancer were significantly higher compared with those in normal tissues ( P < 0.001). IHC results show the high-expression rate of RRBP1 in bladder cancer was 68.8%, which was significantly greater than those in normal tissues (40.6%, P < 0.001). RRBP1 high-expression was significantly associated with differentiation, T stage and lymph node metastasis in bladder cancer ( P < 0.05). The overall survival time of patients with RRBP1 high-expression was significantly reduced compared to those with RRBP1 low-expression. Moreover, RRBP1 overexpression significantly promoted cell proliferation, which was correlated with Smad1/Smad3/TGF-β1 signal pathway. Conclusion RRBP1 high-expression correlates with prognosis and promotes cell proliferation in bladder cancer, which could be a potential biomarker.

show abstract

“…DOX is an e cient anticancer drug that belongs to the anthracycline antibiotics and is commonly used alone or in combination with other chemotherapy agents in the treatment of a broad range of cancers such as lymphoma, leukemia, and also breast, bladder, and kidney cancers [1][2][3][4][5][6]. However, the inability to select target cells, the harmful adverse effects such as cardiotoxicity, and the emergence of drug resistance remain signi cant limitations associated with DOX administration [7,8].…”

Section: Introductionmentioning

confidence: 99%

Formulation of Folate-conjugated, Doxorubicin-loaded Human Serum Albumin Nanoparticles for Promotion of Gene Expression Associated with Apoptosis in Renal Cell Carcinoma

Khalil

Al-Musawi

Albukhaty

et al. 2021

Preprint

View full text Add to dashboard Cite

In this study, we developed a new, efficient targeting and pH-responsive formulation using folate (FA)-conjugated human serum albumin (HSA) nanoparticles to deliver doxorubicin (DOX) drug to renal cell carcinoma. FA was conjugated to HSA, and DOX was loaded into obtained FA-HSA NP using the desolvation method. FA-HSA-DOX NPs were examined using zeta potential and (DLS) measurements, dynamic light scattering, scanning electron microscopy, atomic force microscopy, FTIR, and UV-Vis Spectroscopy. Drug liberation rate, toxicity/viability rate, and the apoptosis/necrosis effect of different DOX, FA-HSA, and FA-DOX-HSA treatments were evaluated using release profile study, MTT assay, and flow cytometry methods, respectively. The expression of BAK, BCL2, BAX, and BCL-XL genes in cancer cells after treatment was analyzed via real-time polymerase chain reaction (PCR). The average size, zeta potential, and polydispersity of FA-DOX-HSA NPs were 200 ± 9 (nm), − 47 ± 7 (mv), and 0.012, respectively. This formulation showed pH-dependent drug release, high drug loading performance, sustained ability of drug release. The notable toxic properties and high apoptosis-stimulation ability of the FA-HAS-DOX NPs in RCC-GH cell lines demonstrated long-term anticancer efficacy. Also, real-time PCR results showed an increase in BAX expression and a decrease in BCL-2 L1 and BCL-XL significantly. Our findings indicate that FA-HSA NPs have no cytotoxic effect on cancer cells (RCC-GH) and healthy cells (RPTEC/TERT1). Our study provides a simple and efficient FA-HSA carrier with intrinsic biocompatibility for DOX drug delivery

show abstract

Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non–muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis

Cited by 9 publications

References 17 publications

Circulating Levels of Epirubicin Cause Endothelial Senescence While Compromising Metabolic Activity and Vascular Function

Circulating Levels of Epirubicin Cause Endothelial Senescence While Compromising Metabolic Activity and Vascular Function

<p>Ribosome Binding Protein 1 Correlates with Prognosis and Cell Proliferation in Bladder Cancer</p>

Formulation of Folate-conjugated, Doxorubicin-loaded Human Serum Albumin Nanoparticles for Promotion of Gene Expression Associated with Apoptosis in Renal Cell Carcinoma

Contact Info

Product

Resources

About